Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 115 clinical trials
Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC

surgical specimen, liquid biopsy, blood and saliva samples) as well as functional imaging (MRI).

  • 0 views
  • 28 Mar, 2021
  • 1 location
Open D3 Right Hemicolectomy Compared to Laparoscopic CME for Right Sided Colon Cancer

quality by comparing actual vascular stump length between the two groups by postoperative CT and compare number of lymph nodes removed with the specimen. With the use of liquid biopsy we want to detect

right hemicolectomy
cancer
circulating tumor cells
lymphadenectomy
colon cancer
  • 0 views
  • 04 Sep, 2021
  • 1 location
Early Detection of Prostate Cancer (PROLIPSY)

Liquid biopsy marker will provide the best discrimination between the patients with histologically proven PCa and age-matched noncancer controls. Further subset analysis with special emphasis on the

  • 0 views
  • 25 Mar, 2022
Evaluation of cfDNA as a Marker of Response in Rectal Cancer

biomarker of response, in liquid biopsy, for rectal cancer. The concentration of baseline plasma cell-free DNA (cfDNA) appears significantly higher in responders compared to non-responders. The

KRAS
EGFR
chemoradiotherapy
adenocarcinoma of rectum
adenocarcinoma
  • 0 views
  • 02 Mar, 2022
  • 1 location
TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

INFINITY is a Phase II, multicentre, single-arm, multi-cohort trial aimed at evaluating the activity and safety of the combination of tremelimumab and durvalumab as neoadjuvant (Cohort and definitive (Cohort 2) treatment for MSI-high gastric/gastroesophageal juction cancer patients eligible for radical surgery.

  • 0 views
  • 13 May, 2021
  • 1 location
PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) (PRELUDE-1)

PRELUDE-1 study is a pilot intervention trial that aims to describe the immunologic and genetic evolutions induced by stereotactic body radiationtherapy (SBRT) treatment in oligometastatic Colorectal Cancer (omCRC) patients with two-three nodules lung-limited disease.

  • 0 views
  • 24 Apr, 2022
A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.

Colorectal cancer remains the commonest cancer among men, and third commonest among women in Saudi Arabia . Presentation with metastatic disease occurs in almost one third of patients , with 5-year survival decreasing significantly from 90% in stage 1 to 14% once the disease is metastatic . There is enthusiasm …

  • 0 views
  • 09 Mar, 2021
  • 1 location
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

This phase II trial studies how well infigratinib works in treating solid tumors that have spread to other places in the body (advanced or metastatic) in patients with FGFR gene mutations such as FGFR1-3 gene fusions or other FGFR genetic alterations. Mutations are any changes in the genetic material (DNA) …

FGFR1
cancer
fgfr inhibitor
cancer treatment
cancer therapy
  • 0 views
  • 26 Mar, 2022
  • 1 location
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study (COPE)

COPE is a biology driven protocol with 2 independent, multicentric, two-arm non-comparative randomized (2:1) phase II trials in 2 distinct populations: colorectal cancer patients and non-small-lung cancer patients. For each phase II trial, patient will be randomized between two arms with two patients randomized in arm A for one patient …

liquid biopsy
lung carcinoma
measurable disease
lung cancer
systemic therapy
  • 0 views
  • 23 Mar, 2022
  • 5 locations
Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage

Screening programs for high-grade ovarian carcinoma failed to reduce disease-specific mortality, since they do not offer early enough detection of the disease. Most cases of high grade ovarian cancer develop in the fallopian tubes, hence the universal recommendation for high-risk populations (e.g., BRCA1/2 mutation carriers) is to undergo risk-reducing bilateral …

ovarian epithelial carcinoma
primary peritoneal carcinoma
cancer
cavity
hysterectomy
  • 8 views
  • 24 Jan, 2021
  • 5 locations